Accelerating Regulatory Review of Medical Products
Long and unpredictable regulatory review can delay promising medicines, vaccines, and other medical products from reaching people who need them. Through institutional strengthening, policy development, and capacity-building efforts, 1Day Sooner works to help regulators make high-quality decisions faster while maintaining rigorous standards for safety and effectiveness.
We believe artificial intelligence can become an important part of this effort. AI-enabled tools have the potential to support regulatory workflows, including dossier review, evidence synthesis, information management, and post-market surveillance. To benefit from the upcoming age of transformative AI, regulators need appropriate governance frameworks, digital infrastructure, technical expertise, and systems for evaluating and assuring the performance of AI tools.
1Day Sooner has advocated for the responsible use of AI to strengthen regulatory review, including at the U.S. Food and Drug Administration. Through our African chapter, 1Day Africa, we are also working with the African Medicines Agency (AMA) and national regulatory authorities across the continent to explore how AI can be responsibly integrated into medicines regulation. Our work focuses on regulatory information management systems, AI governance and policy, institutional capacity, and the technical and organizational foundations needed for AI-assisted regulatory review.
General Questions
-
AMA is an African Union institution created to strengthen and coordinate medicines regulation across the continent. Medicines development is increasingly international, while regulatory capacity and requirements remain fragmented across countries. AMA’s mission is harmonization and reduction in delays in medicines reaching people in need.
Expanded answer:
Africa has more than 50 national medicines regulators with very different levels of staffing, digital infrastructure, technical capacity, and regulatory maturity. A company developing a medicine for use across Africa can therefore face multiple separate submission and review processes.AMA creates an opportunity to strengthen harmonization, reliance, joint assessment, and regulatory capacity across countries. AMA does not replace national regulators. A continental system can preserve national decision-making while making it easier for regulators to share assessments, infrastructure, expertise, and standards.
AMA is especially interesting because it is being built at a time when both clinical research and regulatory technology are changing rapidly. Decisions made now about its systems and policies will shape African medicines regulation for decades.
-
The problem is unnecessary delay between a promising scientific idea and a safe, effective product reaching people who need it.
Expanded answer:
There are unavoidable reasons why medical development takes time. Good science takes time, and regulators must carefully evaluate safety, quality, and efficacy.A trial may take longer because sponsors do not know which regulatory pathway applies. A medicines submission dossier can sit in a backlog queue for months before it reaches the right people. Regulators may repeatedly perform the same administrative checks. Different countries may ask the same sponsor essentially the same questions independently. Promising vaccine candidates may proceed into extremely expensive field trials before researchers have obtained enough early evidence to know which candidate is best.
Our work is trying to solve those avoidable sources of delay. CHIMs address part of the clinical-development problem by generating highly informative evidence earlier. AI and better digital systems address part of the regulatory-process problem by reducing repetitive document handling and administrative work.
-
Because Africa carries a disproportionate burden of infectious disease and it is dramatically underrepresented in clinical research and facing substantial regulatory-capacity constraints.
Expanded answer:
Africa carries roughly a quarter of the global disease burden while hosting only a small fraction of global clinical trials. It means that diseases affecting African populations may receive less research attention, African researchers may have fewer opportunities to shape product development, and evidence used for regulatory decisions may disproportionately come from populations elsewhere.We advocate for increasing African scientific and regulatory capacity so African institutions can help determine which questions are studied, how research is governed, and how evidence is used. That is part of what we mean by regulatory and scientific sovereignty.
-
Not at all. The objective is to get rid of unnecessary delays, but not necessary scrutiny.
Expanded answer:
A regulator taking time to resolve a genuine safety signal is a key part of the process, which we do not want to shorten. But if a regulator is losing months because documents are routed manually, because submissions repeatedly fail basic completeness checks, or because several institutions separately perform almost identical administrative work is a different problem and this is where we see an opportunity to intervene. That principle applies to CHIMs as well. Faster evidence generation is valuable only if participant protections, scientific validity, rescue treatment, monitoring, and ethical oversight remain strong.
CHIMs
-
A CHIM is a controlled study in which consenting volunteers are deliberately (but safely) exposed to an infectious organism so researchers can study infection or test vaccines and treatments under closely monitored conditions.
Expanded answer:
These are sometimes called human challenge trials or HCTs. Strictly speaking, a CHIM is the experimental model and an HCT is a study using that model, although the terms are often used interchangeably.The defining feature is that exposure is planned rather than occurring unpredictably in the community. That allows researchers to know when exposure occurred, what strain or dose was involved, and what participants' immune responses looked like before and after infection. Participants can also be monitored extremely closely and treated according to a predefined protocol.
CHIMs have been used in research involving diseases including malaria, influenza, typhoid, cholera, RSV, pneumococcus and others.
-
Because under the right circumstances, controlled infection can answer important questions much faster and with far fewer participants than waiting for natural infections to occur.
Expanded answer:
In a conventional field trial researchers may need to recruit thousands of people and wait months or years for enough participants to naturally encounter the pathogen.In a CHIM, carefully selected volunteers can receive a vaccine or intervention and subsequently undergo controlled exposure. Researchers can then directly observe whether it prevented infection or reduced disease. That can provide early proof of concept, help identify the right dose, reveal immune correlates of protection, or show that a candidate is unlikely to work before enormous resources are committed to a Phase 3 trial.
-
Deliberate infection creates unusual ethical responsibilities, but it is not inherently unethical. The ethical question is whether the risks are sufficiently understood and minimized, whether volunteers genuinely understand those risks, and whether the scientific value justifies them.
Expanded answer:
Modern CHIMs require particularly strong ethical safeguards precisely because researchers deliberately expose participants.Appropriate studies generally involve carefully characterized pathogens, controlled doses, detailed eligibility criteria, close monitoring, stopping rules, access to treatment or rescue therapy when appropriate, independent ethical review, and clearly documented informed consent.
Well designed challenge studies can have a strong safety record when the pathogen, participants, facilities, and safeguards are appropriate. There will also be pathogens and circumstances for which a CHIM should simply not be conducted because the risks cannot be adequately controlled.
-
No. Our position is the opposite. African researchers, regulators, ethics committees, communities, and participants should have greater power over research involving diseases that heavily affect African populations.
Expanded answer:
Concerns about exploitation are legitimate given the history of medical research. The wrong model would be for outside institutions to choose African populations simply because studies are cheaper or standards are perceived as weaker.The model we support requires strong African regulatory oversight, independent ethics review, meaningful informed consent, fair compensation, appropriate treatment and injury protections, community engagement, and high-quality local research infrastructure. It also means building African institutions capable of setting the rules.
Today, most modern CHIM research has actually occurred outside Africa. Our CHIM database suggests only around 8% of CHIMs conducted or planned since 2015 were in Africa. For diseases such as malaria, that creates a different question: why should most of the specialized infrastructure and scientific expertise for studying diseases concentrated in Africa remain elsewhere?
-
Because they can allow researchers to obtain early evidence about vaccines and treatments for diseases such as malaria much faster than conventional development alone.
Expanded answer:
Many infectious diseases that cause enormous mortality or morbidity in Africa receive fewer commercial research resources than diseases with large wealthy-country markets. Anything that improves the efficiency of product development can therefore matter disproportionately. A good CHIM can help researchers choose between multiple vaccine candidates or dosing strategies before launching large and expensive field trials. Funding money and trial capacity can be focused on candidates with a stronger chance of success. There is also a scientific reason to conduct research closer to affected populations. Prior exposure, genetics, immunity, environment, nutrition, pathogen strains, and other factors can influence results. African research capacity makes it possible to answer questions that may not be answerable from European or North American studies alone. -
Usually no, because they are much smaller. They address a different problem of wasting resources and time.
Expanded answer:
CHIMs typically involve relatively small numbers of carefully selected participants. That makes them extremely useful for proof of concept, dose selection, candidate comparison, and mechanistic research.But a result in a small group of healthy adults does not automatically tell us how a product will perform in children, older people, pregnant women, people with underlying conditions, or a large real-world population. For that reason, CHIM evidence will usually be supportive evidence rather than replacement evidence.
There may be exceptional circumstances where it plays a larger regulatory role for example when field efficacy trials are infeasible, during some public-health emergencies, or where validated correlates of protection make bridging possible.
What is currently missing in much of Africa is clear regulatory guidance explaining when each of those evidentiary roles applies.
-
We need AMA to establish common rules, make high-quality review easier across countries, and clarify how CHIM evidence can be used in regulatory decisions.
Expanded answer:
First, AMA can support a harmonized model policy framework based on the technical work being developed through AVAREF. Countries could adopt or adapt that framework nationally.Second, complex CHIM proposals could have access to a standing continental review mechanism involving expertise in infectious disease, statistics, ethics, biosafety, challenge-agent manufacturing, and clinical care. National regulators would retain authorization powers, but they could rely on a high-quality shared assessment rather than rebuilding rare expertise every time.
Third, AMA can clarify the evidentiary role of CHIMs. Researchers and product developers should know whether CHIM evidence will be treated as exploratory, supportive, contributory to efficacy, or potentially pivotal in exceptional cases.
-
Participants should be compensated fairly for their time, inconvenience, and burdens, but compensation must be structured so that people can still make a genuinely voluntary decision.
Expanded answer:
This is one of the areas where clear guidance is especially valuable. CHIM participants may spend substantial periods in inpatient units, miss work, undergo frequent blood tests and procedures, and accept burdens that ordinary research participants do not.Simply paying very little in the name of avoiding inducement can itself be exploitative. At the same time, compensation should not be designed in a way that overwhelms a person's ability to evaluate risk.
A strong framework should distinguish reimbursement of expenses, compensation for time and burden, and compensation for research-related injury. Amounts and payment schedules should be transparent, ethically reviewed, and appropriate to the local context.
-
The threshold should be much higher in these cases and healthy adults should generally come first.
Expanded answer:
Vulnerable populations create additional ethical and scientific challenges. A challenge model would normally need substantial safety experience in adults before researchers even considered extending it to children. Inclusion would require a compelling scientific rationale, careful age-specific risk assessment, parental permission, appropriate assent, and additional safeguards.Pregnancy similarly requires exceptional caution because an infection may affect both the participant and fetus.There may eventually be scientifically important questions that cannot be answered in any other population, but inclusion should never occur simply for convenience. The principle is progressive evidence generation: begin where uncertainty and potential harm can be most tightly controlled.
-
We think it could in many cases, but preparedness has to happen before the emergency.
Expanded answer:
A challenge model cannot simply be invented overnight when an outbreak begins. Researchers may need a characterized challenge agent, suitable facilities, trained staff, diagnostic capacity, rescue treatments, regulatory and ethics procedures, and strong infection-control systems.If those components already exist, CHIMs can potentially help answer questions about transmission, immunity, vaccines, treatments, and correlates of protection much faster during an emergency.
COVID-19 demonstrated both the potential value of challenge research and how much scientific, ethical, manufacturing, and regulatory preparation it requires. We need to build the capability and governance in advance so the option can be evaluated responsibly when time matters.
AI in medicines regulation
-
Primarily as a regulatory assistant to reduce delays that are now happening because of initial steps in the process, but final decisions would be made by humans.
Expanded answer:
Medicines regulation involves large quantities of documents. Before a human reaches a difficult scientific judgment, somebody may need to check whether all required documents are present, extract data from hundreds of pages, compare different versions, search earlier regulatory decisions, summarize correspondence, or consolidate questions for an applicant.Modern AI systems are increasingly good at exactly these document-heavy, structured tasks. Potential applications can include
dossier completeness screening;
intake and validation checks;
risk-based triage;
extracting information into structured templates;
summarizing large submissions with links back to source material;
comparing different parts or versions of a dossier;
identifying contradictions or missing updates;
searching earlier regulatory decisions and precedents;
drafting questions or deficiency letters for reviewer approval;
assisting with redaction and confidentiality screening.
-
Not at all. The future is uncertain but not in the immediate future.
Expanded answer:
At least in the foreseeable future, final scientific and regulatory responsibility should remain with qualified humans. The most credible near-term AI applications are bounded tasks where outputs can be checked against source documents.An AI system might flag that two sections of a dossier report different numbers of adverse events. A reviewer should determine why. It might draft a summary of a clinical study. A reviewer should validate that summary. It might identify that a required document appears to be missing. A regulatory officer should confirm that finding.
-
It would be dangerous if regulators trusted an AI system blindly. That is why regulatory AI needs a very different deployment model from a public model. And this is why our work is partially to establish and support strong AI governance structures.
Expanded answer:
A serious regulatory system should have controlled access, strong data governance, audit logs, version control, documented validation, clear task boundaries, and human verification.Outputs should be traceable back to the original source material wherever possible. Systems should be evaluated on regulatory tasks before deployment, including on previously unseen examples. Error rates should be measured rather than assumed. And different tasks should have different thresholds. A system that helps locate paragraphs in a dossier can tolerate a different risk profile from a system producing information that influences a safety assessment.
-
That is exactly why the digital and AI strategies need to be designed together, and why all our proposals start with key infrastructure, capacity building and training.
Expanded answer:
AI is not a substitute for basic infrastructure. Our research found highly uneven digital maturity among African medicines regulators. Many still lack modern regulatory information-management systems, integrated electronic submissions, or interoperable platforms. If AI is simply layered onto fragmented or poorly digitized processes, it will deliver limited value.But AMA is unusual because much of its own digital infrastructure is still being established. That creates the opportunity to design systems that are digital-first and AI-ready rather than building a legacy architecture now and trying to retrofit it later. So we need to build good digital infrastructure, good data governance, and then appropriately governed AI capabilities embedded into those systems.
-
The largest early gains are likely to come from reducing time spent on administrative and document-heavy stages of review.
Expanded answer:
African regulatory delays are not caused by one single bottleneck. But some remarkably long delays occur before or around substantive scientific assessment.Our research highlights validation, routing, administrative screening, information extraction, repetitive queries, and document handling as areas where substantial time is consumed. Stakeholders we consulted estimated that structured screening, automated triage and AI-assisted document handling could potentially reduce the time spent on some of these stages very substantially, sometimes by as much as 80%.
We should be careful not to turn that into a promise that overall approval times will fall by 80%. They will not. The point is that if a regulator can automate hours of low-value document work, expert staff have more time available for difficult scientific assessment.
-
Major regulators around the world are already moving in this direction.
Expanded answer:
The FDA has begun deploying generative-AI tools to support internal scientific and regulatory work, including its agency-wide Elsa system.In Europe, EMA and the Heads of Medicines Agencies have issued principles governing large-language-model use and have developed AI-enabled tools for regulatory information retrieval and related tasks.
Of course AMA should not simply copy the FDA or EMA. Those agencies operate with very different resources and institutional histories. The lesson is that AI-assisted regulatory work has moved from a hypothetical discussion to an operational one. Africa therefore has an opportunity to learn from early adopters while designing systems specifically for its own needs.
-
It could, if the systems are designed badly. Sovereignty therefore needs to be part of the architecture from the beginning.
Expanded answer:
Regulatory dossiers contain commercially sensitive information and potentially sensitive health information. Regulators cannot simply upload them indiscriminately to consumer AI products.AMA and national regulators should establish rules governing where data can be stored, who can access it, how models are evaluated, how vendors are selected, what happens to submitted data, and how regulators can change providers later.
Local hosting or other strong data-control arrangements may be appropriate for sensitive use cases. African implementation partners also matter because technical deployment has to work within actual regulatory workflows and institutional realities.
At the same time, there is no reason to reject global technical expertise simply because it comes from outside Africa. The goal should be internationally informed but locally governed systems, with African public institutions retaining control over data, standards, procurement, and regulatory decisions.
-
Yes it could, but we can design common infrastructure deliberately to prevent that.
Expanded answer:
If only the best resourced national regulators can afford advanced digital and AI systems, the regulatory-capacity gap could widen. But we believe that AMA provides a potential alternative. Instead of every country independently purchasing and maintaining sophisticated technology, AMA could support shared continental infrastructure with configurable national workspaces.That could allow smaller regulators to access modern submission, workflow, information-management, and AI-assistance capabilities while retaining their own decision-making authority. Done well, shared infrastructure becomes a capacity equalizer. Done poorly, it could create dependence on a centralized system or vendor. Governance and long-term financing therefore matter just as much as the technology.
Other questions
-
Technically they are different, but they address the same underlying problem: how to get safe and effective medical products to people faster without lowering standards.
Expanded answer:
CHIMs operate primarily on the research-development side. They can produce highly informative biological and efficacy data earlier in development and help determine which interventions deserve larger trials.AI operates primarily on the regulatory-process side. It can reduce the administrative burden involved in receiving, organizing, searching, comparing, and reviewing the evidence generated by studies.
The common principle is that scarce scientific expertise should be spent on difficult scientific questions rather than avoidable inefficiency.
Both also require strong governance. A poorly governed CHIM can expose participants to unacceptable risk. A poorly governed AI system can introduce errors, confidentiality problems, or unclear accountability. So acceleration and governance have to develop together.
-
These tools do not replace basic health-system investment…
Expanded answer:
A CHIM cannot responsibly operate in a facility that lacks the clinical capacity required to care for participants. AI cannot compensate for the complete absence of trained regulatory staff, reliable electricity, cybersecurity, or basic information systems.Our work explicitly recognizes these constraints. Once institutions are investing in regulatory and research capacity, they should design it in ways that avoid recreating inefficient systems.
And some investments have spillover benefits. A CHIM facility requires strong laboratories, clinical monitoring, biosafety, trained personnel, and emergency-care capability. Those resources can strengthen broader clinical-research capacity. Similarly, a good regulatory digital platform can improve ordinary medicines review even before sophisticated AI functions are added.
-
It means African institutions having the expertise, infrastructure, rules, and decision-making power to govern medicines development for African populations.
Expanded answer:
We think that sovereignty is being able to evaluate evidence rather than relying automatically on foreign decisions, having African scientists and regulators involved in designing standards, controlling sensitive regulatory data. It means having the capability to conduct high-quality studies relevant to African disease priorities, local manufacturing and local responsibility. -
Success would be durable sustainable institutions and a few well-designed systems that demonstrate the model, and a meaningful reduction in backlogs and timelines. It would also mean much better preparedness for pandemics and more institutional autonomy.
Expanded answer:
For CHIMs, credible near-term progress would include:an AMA-backed continental CHIM framework;
clearer standards for ethics, compensation, safety, biosafety and participant protection;
a predictable mechanism for expert review of complex CHIM proposals;
guidance explaining how CHIM evidence can contribute to regulatory submissions;
stronger African CHIM research infrastructure and regulatory expertise; and
successful, scientifically important studies conducted under those standards.
On AI and digital regulation:
an internal AMA AI-governance structure;
clear rules for appropriate and inappropriate regulatory AI uses;
modern digital submission and regulatory-information infrastructure;
carefully evaluated pilots for low-risk AI-assisted tasks;
shared infrastructure or guidance that national regulators can use;
staff training and auditing mechanisms; and
a sustainable financing model for maintaining these systems beyond initial donor grants.
-
Public-interest infrastructure and capacity that lasts for many years.
Expanded answer:
There is often plenty of enthusiasm for funding an exciting technology demonstration. The harder problem is paying for the governance, integration, staff training, maintenance, cybersecurity, evaluation, and long-term institutional ownership that make a system actually useful.The same applies to CHIMs. Funding a single study is valuable, but building regulatory expertise, research facilities, challenge-agent capacity, clinical-care infrastructure, ethics capacity, and predictable policy can support an entire research ecosystem.
The highest-return investment may therefore be the less glamorous one: building institutions that continue functioning after the initial grant ends.
-
Commercial companies can benefit from faster development and more predictable regulation, but the public-interest case depends on patients and health systems benefiting as well.
Expanded answer:
There is nothing inherently wrong with reducing unnecessary costs for a company developing a useful medicine. The policy question is whether faster development and regulation also produce public value.That can include earlier access to effective products, better research infrastructure, stronger regulators, lower administrative burdens, more clinical research conducted in Africa, and improved pandemic preparedness.
Public institutions should therefore structure partnerships so that technology transfer, local capacity, public governance, sustainability, and accessibility are built into the arrangement.
-
The regulator must retain accountability for the regulatory decision.
Expanded answer:
This is another reason we oppose treating AI as an autonomous decision-maker. There should be an explicit chain of responsibility covering the software provider, system operator, reviewer, institution, and final decision-maker.Every consequential output should be reviewable and auditable. Regulators also need incident-reporting systems so errors can be detected, investigated, and used to improve the system. The phrase "the AI decided" should never become an acceptable explanation for a regulatory decision.
-
Because they only make sense when the scientific question and risk profile are suitable.
Expanded answer:
Some infections cannot be reliably treated. Some can produce severe disease. Some challenge models do not reproduce natural infection well enough to answer the question researchers care about.There may also be no ethical justification for deliberate exposure when the scientific information could readily be obtained through safer methods. CHIMs are therefore a specialized research tool, not a universal substitute for conventional trials. Their value comes from using them selectively where the information gained is unusually valuable relative to the risks and burdens involved.
-
Not really. Speed matters to companies, AND it matters to patients. During the COVID pandemic, interventions reaching patients one day sooner could have saved 10,000s of lives daily.
Expanded answer:
When a useful vaccine or treatment arrives a year later than necessary, the cost is not only lost commercial revenue.People spend that additional year becoming sick, transmitting infection, or dying without access to the intervention.Speed should never become an excuse to accept weak evidence. But once safety and scientific standards are held constant, unnecessary delay has a real human cost. That is why regulatory efficiency should be understood as a public-health issue.
-
We think that it’s that acceleration requires lowering standards.
Expanded answer:
Many of the opportunities we are discussing actually come from applying standards more intelligently. A good CHIM can generate cleaner, highly controlled evidence rather than weaker evidence. A good AI system can allow a regulator to spend more time evaluating scientific uncertainty rather than formatting documents. A harmonized review pathway can bring more specialized experts into a difficult decision rather than fewer. We are not advocating for deregulation or lower standards, but better regulation and better science with less avoidable friction. -
We are primarily funded by philanthropic organizations and individual donors who want to use their resources to address large global health problems in ways that can have lasting impact.
Extended answer:
1Day Sooner is a nonprofit, and most of our funding comes from philanthropic grants. We also receive donations from individuals.Our funders tend to be interested in neglected opportunities where relatively targeted investments could produce large public-health benefits, for example, accelerating medical research, improving pandemic preparedness, or strengthening regulatory systems.
-
It varies a lot depending on whether we are doing policy research and convening stakeholders or helping build actual institutional infrastructure.
Extended answer:
A relatively small amount of funding can support policy research, stakeholder engagement, regulatory analysis, convenings, and early project development.Building durable regulatory infrastructure is obviously more expensive. Digital platforms, cybersecurity, staff, training, AI validation, system integration, technical support, and long-term maintenance all require substantial investment.
For example, our initial work exploring opportunities around AMA and AI-assisted medicines regulation was a relatively modest scoping project. A serious multi-country implementation program, by contrast, could require investment on the order of millions of dollars over several years.
The relevant comparison is the value of the system being improved. Medicines regulation affects thousands of products and hundreds of millions of people. If better infrastructure meaningfully reduces regulatory bottlenecks across multiple countries, the benefits can persist long after the initial investment.
We therefore look less at whether a project is inexpensive in absolute terms and more at whether its expected public-health value justifies its cost.
-
We prioritize projects that build sustainable institutional capacity rather than systems that require permanent philanthropic funding.
Extended answer:
A successful project should not collapse when the original grant ends. That means sustainability has to be designed in from the beginning rather than discussed at the end of a funding cycle. For regulatory infrastructure, potential long-term financing mechanisms include regulatory user fees, member-country contributions, shared regional infrastructure, and ordinary institutional budgets.Philanthropy can be particularly useful for absorbing the initial costs of experimentation, system development, training, and implementation. But once something proves useful, the institution using it should ideally have a realistic mechanism for maintaining it.
The same principle applies to expertise. We want to transfer knowledge, documentation, systems, and technical capacity to African institutions rather than create permanent dependence on an outside organization. So in the future our goal is ultimately to make ourselves less necessary, not more necessary.
-
1Day Sooner began during COVID-19 in 2020 as a movement representing people willing to volunteer for human challenge studies to accelerate vaccine development. It has since grown into a broader global-health organization working on clinical research, pandemic preparedness, and policies that can accelerate access to lifesaving medical technologies.
Extended answer:
1Day Sooner was founded in March 2020, early in the COVID-19 pandemic. At the time, researchers were debating whether controlled human infection studies could contribute to faster COVID vaccine development. Tens of thousands of people came forward saying that, if such studies were scientifically useful and ethically approved, they would be willing to volunteer. 1Day Sooner was created in part to give those potential research participants a voice in a debate that was largely taking place among scientists, ethicists, regulators, and policymakers. More than 40,000 people have since expressed interest through the organization in participating in early-phase medical research.As the pandemic evolved, the organization broadened its work. It became involved in human challenge research for other diseases, pandemic preparedness, vaccine policy, clinical-trial participation, and questions about how medical research can be conducted more efficiently and equitably.
-
The organization is evolving from advocating for faster research toward addressing some of the systems that determine how quickly medical innovation actually reaches people.
-
We started with challenge trials, but the underlying problem we work on is avoidable delay in medical innovation.
Extended answer:
Human challenge trials were our starting point because they offered an example of a potentially underused tool that could accelerate medical research. Once you look at the full path from scientific discovery to a medicine reaching patients, clinical trials are only one part of it. Regulatory bottlenecks, fragmented systems, manufacturing constraints, financing, and access can each add months or years. Our work has therefore expanded toward interventions where we think relatively neglected policy or institutional changes could produce substantial improvements in health. -
It should not be our role to dictate African health policy, but to support African institutions that hold the mandate and authority to make those decisions.
